Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC

Overview

Journal Curr Treat Options Oncol

Specialty Oncology

Date 2019 Sep 5

PMID 31482479

Citations 19

Authors

Alex Friedlaender

Giuseppe Banna

Sandip Patel

Alfredo Addeo

Affiliations

Soon will be listed here.

Abstract

There has been rapid progress in the use of targeted therapies for ALK-positive which has led to improve dramatically PFS and OS in the metastatic ALK-rearranged NSCLC patients. There are several molecules now available (crizotinib, ceritinib, brigatinib, alectinib, and lorlatinib) and others in development. Such an improvement in treatment efficacy has even more highlighted the importance of an adequate identification of ALK alterations. Efficient and easily accessible testing tools are required to identify eligible patients in a timely fashion. Different methods for detecting ALK+ NSCLC patients are now available, with fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) currently representing validated diagnostic techniques for the initial assessment of ALK status. Furthermore the widespread use of next-generation sequencing to detect other possible different activating mutations has allowed to identify individual ALK fusion variants. Several more expensive and time-consuming methods are also available nowadays which have the advantage to detect even rarer uncommon ALK fusion variants and mutations in tumour or blood samples. A review of the evolving testing-treatment landscape is needed to highlight the importance of properly diagnosing and treating this group of patients.

Citing Articles

A Comprehensive Review of Advances in Molecular Mechanisms and Targeted Therapies for the Specific Type of Cystic Lung Cancer.

Wang B, Shen C, Liu D, Dong Z, Lin X, Liao H Onco Targets Ther. 2025; 18:211-224.

PMID: 39959914 PMC: 11829588. DOI: 10.2147/OTT.S495018.

The Use of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer Treatment-Literature Review.

Gorzelak-Magiera A, Domagala-Haduch M, Kabut J, Gisterek-Grocholska I Biomedicines. 2024; 12(10).

PMID: 39457620 PMC: 11504905. DOI: 10.3390/biomedicines12102308.

Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis.

Filetti M, Lombardi P, Falcone R, Giusti R, Giannarelli D, Carcagni A Explor Target Antitumor Ther. 2024; 4(6):1136-1144.

PMID: 38213541 PMC: 10784113. DOI: 10.37349/etat.2023.00187.

From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC).

Fabbri L, Di Federico A, Astore M, Marchiori V, Rejtano A, Seminerio R Diagnostics (Basel). 2024; 14(1).

PMID: 38201357 PMC: 10804309. DOI: 10.3390/diagnostics14010048.

Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma.

Zheng Z, Ku H, Chen K, Chiang C, Wang C, Chen C Front Oncol. 2023; 13:1063695.

PMID: 37007097 PMC: 10064125. DOI: 10.3389/fonc.2023.1063695.

References

Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart M . Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000; 157(5):1467-72. PMC: 1885742. DOI: 10.1016/S0002-9440(10)64785-2. View

Lambros M, Natrajan R, Reis-Filho J . Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol. 2007; 38(8):1105-22. DOI: 10.1016/j.humpath.2007.04.011. View

Choi Y, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S . Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 2008; 68(13):4971-6. DOI: 10.1158/0008-5472.CAN-07-6158. View

Wong D, Leung E, So K, Tam I, Sihoe A, Cheng L . The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009; 115(8):1723-33. DOI: 10.1002/cncr.24181. View

Palmer R, Vernersson E, Grabbe C, Hallberg B . Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009; 420(3):345-61. PMC: 2708929. DOI: 10.1042/BJ20090387. View

Rodig S, Mino-Kenudson M, Dacic S, Yeap B, Shaw A, Barletta J . Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009; 15(16):5216-23. PMC: 2865649. DOI: 10.1158/1078-0432.CCR-09-0802. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Kwak E, Bang Y, Camidge D, Shaw A, Solomon B, Maki R . Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363(18):1693-703. PMC: 3014291. DOI: 10.1056/NEJMoa1006448. View

Camidge D, Kono S, Flacco A, Tan A, Doebele R, Zhou Q . Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010; 16(22):5581-90. PMC: 3395226. DOI: 10.1158/1078-0432.CCR-10-0851. View

10.

Camidge D, Kono S, Lu X, Okuyama S, Baron A, Oton A . Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 2011; 6(4):774-80. PMC: 3626562. DOI: 10.1097/JTO.0b013e31820cf053. View

11.

Kim H, Yoo S, Choe J, Paik J, Xu X, Nitta H . Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol. 2011; 6(8):1359-66. DOI: 10.1097/JTO.0b013e31821cfc73. View

12.

Doebele R, Pilling A, Aisner D, Kutateladze T, Le A, Weickhardt A . Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012; 18(5):1472-82. PMC: 3311875. DOI: 10.1158/1078-0432.CCR-11-2906. View

13.

Camidge D, Theodoro M, Maxson D, Skokan M, OBrien T, Lu X . Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer. 2012; 118(18):4486-94. PMC: 3342464. DOI: 10.1002/cncr.27411. View

14.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

15.

Peled N, Palmer G, Hirsch F, Wynes M, Ilouze M, Varella-Garcia M . Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012; 7(9):e14-6. PMC: 3645938. DOI: 10.1097/JTO.0b013e3182614ab5. View

16.

Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, Fujita Y . A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res. 2012; 18(20):5682-9. DOI: 10.1158/1078-0432.CCR-11-2947. View

17.

Weickhardt A, Aisner D, Franklin W, Varella-Garcia M, Doebele R, Camidge D . Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer. 2013; 119(8):1467-77. PMC: 3935240. DOI: 10.1002/cncr.27913. View

18.

Huang D, Kim D, Kotsakis A, Deng S, Lira P, Ho S . Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. Genomics. 2013; 102(3):157-62. DOI: 10.1016/j.ygeno.2013.02.006. View

19.

Shaw A, Kim D, Nakagawa K, Seto T, Crino L, Ahn M . Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368(25):2385-94. DOI: 10.1056/NEJMoa1214886. View

20.

Pikor L, Ramnarine V, Lam S, Lam W . Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013; 82(2):179-89. DOI: 10.1016/j.lungcan.2013.07.025. View